Strata Skin Sciences, Inc. SSKN
0.01
0.00
0.00%
as of 25 Sep
- Market cap
- $1.0M
- P/E
- 0.0×
Follow SSKN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Mar '25 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.33 | 0.29 | 0.30 | 0.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.02) | (4.92) | (144.24) | (24.52) | |
P/B ratio |
4.13 | 31.01 | 7.03 | 2.02 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.56 | 0.59 | 0.56 | 0.87 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
42.54 | (9.22) | (9.43) | (9.57) | |
EV/FCF |
(28.15) | (6.89) | (4.97) | (6.27) | |
Quick Ratio |
0.85 | 0.71 | 0.70 | 0.45 | |
Current Ratio |
1.05 | 0.98 | 0.95 | 0.58 | |
Net Debt/EBITDA |
(11.01) | (10.57) | (45.24) | 4.49 | |
Debt/Assets |
44.45% | 49.70% | 49.84% | 50.29% | |
Debt/Equity |
5.71 | 49.58 | 11.65 | 5.28 | |
Asset Turnover |
0.90 | 0.93 | 0.87 | 0.94 | |
Operating CF/Net income |
0.23 | 0.78 | 0.04 | (0.85) | |
Capex/Depreciation |
(0.15) | 0.05 | (1.03) | (0.33) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.41% | 1.12% | 2.48% | 0.72% | |
Selling, General and Administrative Expense of Revenue |
81.71% | 84.09% | 84.70% | 58.29% | |
Intangible Assets out of Total Assets |
0.22 | 0.23 | 0.18 | 0.16 | |
Share Based Compensation of Revenue |
1.89% | 1.67% | 3.06% | 1.87% | |
Graham Net Nets |
(1.43) | (1.74) | (1.64) | (2.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(85.98%) | (124.02%) | (129.61%) | (111.90%) | |
Free Cash Flow Yield |
(6.07%) | (29.25%) | (38.04%) | (72.73%) | |
Revenue per Share |
1.63 | 1.84 | 1.55 | 2.00 | |
Operating CF per Share |
(0.13) | (0.47) | (0.01) | (0.05) | |
Capex per Share |
(0.05) | 0.01 | (0.23) | (0.07) | |
Free Cash Flow per Share |
(0.18) | (0.45) | (0.24) | (0.12) | |
Cash per Share |
1.88 | 1.43 | 1.58 | 1.70 | |
Shareholders Equity per Share |
0.64 | 0.07 | 0.29 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.64 | 0.07 | 0.29 | 0.63 | |
Free Cash Flow |
(0.75) | (1.88) | (1.08) | (0.55) | |
Working Capital |
0.74 | (0.23) | (0.76) | (11.14) | |
Capital Expenditures |
(0.20) | 0.06 | (1.02) | (0.31) | |
Net Current Asset Value |
(15.72) | (16.64) | (15.13) | (12.01) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | (0.01) | 0.15 | 0.03 | |
Net Profit Margin |
(35.70%) | (32.48%) | (23.41%) | 3.03% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.32 | 4.00 | 3.97 | 4.69 | |
Average Payables |
3.20 | 2.92 | 2.35 | 2.60 | |
Average Inventory |
2.68 | 2.96 | 2.90 | 2.53 | |
Average Assets |
37.16 | 35.15 | 35.46 | 32.72 | |
Average Common Equity |
6.05 | 4.90 | 5.33 | 3.94 |
Columns are period end dates